Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

SANSERT

METHYSERGIDE MALEATE

Standard Dose
2MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary

Approval overview SANSERT is listed in Drugs@FDA under application 012516 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient METHYSERGIDE MALEATE Form and strength TABLET;ORAL - 2MG Sponsor NOVARTIS Submission history Latest submission status date: 2001-12-03 00:00:00.

Structured Monograph

Clinical summary

Approval overview SANSERT is listed in Drugs@FDA under application 012516 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient METHYSERGIDE MALEATE Form and strength TABLET;ORAL - 2MG Sponsor NOVARTIS Submission history Latest submission status date: 2001-12-03 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.